Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma

Cytokine

Volumn 49, Issue 1, 2010, Pages 80-88

  Petersen, Charlotte Christie ^a   Diernaes, Jon Erik Fraes ^a   Skovbo, Anni ^a   Hvid, Malene ^a,b   Deleuran, Bent ^a,b   Hokland, Marianne ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adoptive cell transfer; Chemoimmunotherapy; Cyclophosphamide; Interleukin 21; Malignant melanoma

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 21; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; C57BL 6 MOUSE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL STIMULATION; CELL THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HOMOZYGOTE; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFER; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN CELL; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; INTERLEUKINS; KAPLAN-MEIERS ESTIMATE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SPLEEN; T-LYMPHOCYTES;

MURINAE; MUS;

EID: 71649096034     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.11.001     Document Type: Article

References (40)

1. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., and Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 (2006) 383-393
2. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., and Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8 (2008) 299-308
3. Dudley M.E., and Rosenberg S.A. Adoptive cell transfer therapy. Semin Oncol 34 (2007) 524-531
4. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. [see comment]. J Clin Invest 110 (2002) 185-192
5. Maine G.N., and Mule J.J. Making room for T cells. [comment]. J Clin Invest 110 (2002) 157-159
6. Zitvogel L., Apetoh L., Ghiringhelli F., and Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 (2008) 59-73
7. Schiavoni G., Mattei F., Di Pucchio T., Santini S.M., Bracci L., Belardelli F., et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95 (2000) 2024-2030
8. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155 (1982) 1063-1074
9. Turk J.L., and Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 65 (1982) 99-113
10. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
11. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
12. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006) 595-601
13. Boyman O., Purton J.F., Surh C.D., and Sprent J. Cytokines and T-cell homeostasis. Curr Opin Immunol 19 (2007) 320-326
14. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
15. Holm C., Nyvold C.G., Paludan S.R., Thomsen A.R., and Hokland M. Interleukin-21 mRNA expression during virus infections. Cytokine 33 (2006) 41-45
16. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 178 (2007) 2827-2834
17. di Carlo E., de Totero D., Piazza T., Fabbi M., and Ferrini S. Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol Immunother 56 (2007) 1323-1334
18. Skak K., Kragh M., Hausman D., Smyth M.J., and Sivakumar P.V. Interleukin 21: combination strategies for cancer therapy. [erratum appears in Nat Rev Drug Discov 2008;7(3):272]. Nat Rev Drug Discov 7 (2008) 231-240
19. + T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 56 (2007) 1417-1428
20. Spolski R., and Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Ann Rev Immunol 26 (2008) 57-79
21. Brown D.M., Fisher T.L., Wei C., Frelinger J.G., and Lord E.M. Tumours can act as adjuvants for humoral immunity. Immunology 102 (2001) 486-497
22. + T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30 (2007) 40-53
23. + T cells for adoptive immunotherapy. Blood 111 (2008) 5326-5333
24. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13 (2007) 644-653
25. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34 (2004) 336-344
26. Liu J.Y., Wu Y., Zhang X.S., Yang J.L., Li H.L., Mao Y.Q., et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 56 (2007) 1597-1604
27. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105 (2005) 2862-2868
28. Mihalyo M.A., Doody A.D., McAleer J.P., Nowak E.C., Long M., Yang Y., et al. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol 172 (2004) 5338-5345
29. + T-cell responses induced by interleukin 21. Clin Cancer Res 14 (2008) 6125-6136
30. Petersen C.C., Petersen M.S., Agger R., and Hokland M.E. Accumulation in tumor tissue of adoptively transferred T cells: a comparison between intravenous and intraperitoneal injection. J Immunother 29 (2006) 241-249
31. Skak K., Sondergaard H., Frederiksen K.S., and Ehrnrooth E. In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics. Cytokine 24 (2009) 24
32. Fantini M.C., Rizzo A., Fina D., Caruso R., Becker C., Neurath M.F., et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 37 (2007) 3155-3163
33. + T lymphocytes. J Immunol 178 (2007) 732-739
34. + regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol 67 (2008) 37-46
35. Elsaesser H., Sauer K., and Brooks D.G. IL-21 is required to control chronic viral infection. Science 324 (2009) 1569-1572
36. Yi J.S., Du M., and Zajac A.J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324 (2009) 1572-1576
37. Ahmadzadeh M., Antony P.A., and Rosenberg S.A. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother 30 (2007) 294-302
38. Everds N. Hematology of the laboratory mouse. In: The mouse in biomedical research. Elsevier Inc.; 2007. p. 48.
39. Quimby F., and Chaplin D. Overview of immunology in the mouse: molecular and cellular immunology (2007), Elsevier Inc. p. 43
40. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 57 (2008) 1439-1449